

## Form DQT-W: Worksheet for Designing Individual Field Trials under Reward® INAD 10-969

### INSTRUCTIONS

1. Investigator must fill out Form DQT-W for each trial conducted under this INAD **before** actual use of Reward®. The Investigator is responsible that Form DQT-W is completed accurately.
2. Investigator should keep the original on file, and Fax a copy to the Study Monitor for review.
3. After review, the Study Monitor will fax a copy to the AADAP Office for assignment of the Study Number.
4. The AADAP Office will review the worksheet, and then fax the assigned trial Study Number to both the Investigator and Study Monitor, at which time the trial may be initiated.
5. **Note:** Both Investigator and Study Monitor should sign and date Form DQT-W.

### **SITE INFORMATION**

Facility			
Address			
Investigator			
Reporting Individual (if not Investigator)			
Phone		Fax	

### **FISH CULTURE AND DRUG TREATMENT INFORMATION**

Fish species to be treated		Disease to be treated	
Average fish weight (gm)		Average fish length (in)	
No. of fish per unit (e.g. 10,000 fish/raceway)			
Number of treated units		Number of treated fish	
Number of untreated control units		Number of control fish	
Anticipated date treatment will be initiated		Anticipated number of treatments	
Duration of drug treatment (hours)		Check type of treatment	<input checked="" type="checkbox"/> Disease control
Check type of treatment method used		___ Flow through    ___ Standing bath	
Intended drug target dosage (mg/L)	2-18 mg/L 19-28 mg/L	Estimated total amount of drug needed for proposed treatment (ml)	
Drug manufacturer	<b>Syngenta</b>	Drug lot number	

**STUDY DESIGN:** Describe in detail the purpose of the clinical trial. For example you might compare dosage, treatment frequency, or treatment method (Flow-Through vs. Standing Bath). Study design must be carefully focused and lend itself to rigorous evaluation. If more space is required to describe study details, title additional page(s) "Study Design" and attach them to this Worksheet.

Study designed by \_\_\_\_\_

### **DISPOSITION OF TREATED FISH (Human Food Safety Considerations):**

\_\_\_\_\_ Estimated time (days, months) from last treatment day to first possible harvest for human consumption

Check applicable box(es):

Study Objective A - Withdrawal period of 5 days for channel catfish, muskellunge, tiger muskellunge, and northern pike.

Study Objective B - Withdrawal period of 30 days for all other species.

Investigator should initial here to indicate awareness that fish disposition must be in compliance with FDA-mandated withdrawal times as described in Section XV, page 15 of the Study Protocol.

### **WORKER SAFETY CONSIDERATIONS:**

Investigator should initial here to indicate that all personnel handling drug have read Material Safety Data Sheet for Reward® and have been provided protective equipment, in good working condition, as described in the MSDS.

**Date Prepared:** \_\_\_\_\_

**Investigator:** \_\_\_\_\_

**Date Reviewed:** \_\_\_\_\_

**Study Monitor:** \_\_\_\_\_